DE69933989D1 - Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten - Google Patents

Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten

Info

Publication number
DE69933989D1
DE69933989D1 DE69933989T DE69933989T DE69933989D1 DE 69933989 D1 DE69933989 D1 DE 69933989D1 DE 69933989 T DE69933989 T DE 69933989T DE 69933989 T DE69933989 T DE 69933989T DE 69933989 D1 DE69933989 D1 DE 69933989D1
Authority
DE
Germany
Prior art keywords
prostate cancer
treatment
methods
differentially expressed
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933989T
Other languages
English (en)
Other versions
DE69933989T2 (de
Inventor
Gang An
W Veltri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianon Systems Inc
Original Assignee
Dianon Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dianon Systems Inc filed Critical Dianon Systems Inc
Priority claimed from PCT/US1999/001103 external-priority patent/WO1999037811A1/en
Application granted granted Critical
Publication of DE69933989D1 publication Critical patent/DE69933989D1/de
Publication of DE69933989T2 publication Critical patent/DE69933989T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G01N2333/91085—Transglutaminases; Factor XIIIq (2.3.2.13)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69933989T 1998-01-21 1999-01-19 Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten Expired - Lifetime DE69933989T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10398 1998-01-21
US09/010,398 US5972615A (en) 1998-01-21 1998-01-21 Biomarkers and targets for diagnosis, prognosis and management of prostate disease
PCT/US1999/001103 WO1999037811A1 (en) 1998-01-21 1999-01-19 Biomarkers and targets for diagnosis, prognosis and management of prostate disease

Publications (2)

Publication Number Publication Date
DE69933989D1 true DE69933989D1 (de) 2006-12-28
DE69933989T2 DE69933989T2 (de) 2007-07-05

Family

ID=21745589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933989T Expired - Lifetime DE69933989T2 (de) 1998-01-21 1999-01-19 Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten

Country Status (5)

Country Link
US (3) US5972615A (de)
AT (1) ATE345399T1 (de)
AU (1) AU746142B2 (de)
CA (3) CA2707152A1 (de)
DE (1) DE69933989T2 (de)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698152B2 (en) 1994-08-20 1998-10-22 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US7169556B2 (en) 1996-07-29 2007-01-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
ES2287956T3 (es) 1996-07-29 2007-12-16 Nanosphere Inc. Nanoparticulas que tienen oligonucleotidos unidos a las mismas y usos de las mismas.
US6984491B2 (en) * 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6506564B1 (en) * 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7098320B1 (en) 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US20020172953A1 (en) * 1996-07-29 2002-11-21 Mirkin Chad A. Movement of biomolecule-coated nanoparticles in an electric field
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6974669B2 (en) * 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US20050037397A1 (en) * 2001-03-28 2005-02-17 Nanosphere, Inc. Bio-barcode based detection of target analytes
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
CA2321938C (en) 1998-03-02 2009-11-24 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6977154B1 (en) 1998-03-17 2005-12-20 Gendaq Limited Nucleic acid binding proteins
CA2323638A1 (en) * 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US20080050836A1 (en) * 1998-05-01 2008-02-28 Isabelle Guyon Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
EP1121198A1 (de) * 1998-10-14 2001-08-08 Arizona Board of Regents Immobilisiertes silberimmunoassaysystem
WO2000033079A1 (en) 1998-11-30 2000-06-08 Nanosphere, Inc. Nanoparticles with polymer shells
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7013219B2 (en) * 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US20030104526A1 (en) * 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
AU1966201A (en) * 1999-10-20 2001-04-30 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
US6703208B1 (en) 1999-10-20 2004-03-09 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
IL150069A0 (en) * 1999-12-06 2002-12-01 Sangamo Biosciences Inc Methods of using randomized libraries of zinc finger proteins for the identification of gene function
EP1294930B1 (de) 2000-01-13 2011-03-30 Nanosphere, Inc. Nanopartikel an denen oligonukleotide gebunden sind und deren verwendungen
AU2693501A (en) * 2000-01-24 2001-07-31 Gendaq Ltd Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
CA2415494C (en) * 2000-07-11 2007-09-18 Northwestern University Method of detection by enhancement of silver staining
AU2002218786A1 (en) 2000-07-12 2002-01-21 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
NZ526708A (en) * 2000-11-28 2005-07-29 Wyeth Corp Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
MXPA03004579A (es) * 2000-11-28 2003-09-04 Wyeth Corp Analisis de expresion de acidos nucleicos del regulador de cromatina dependiente de actina y polipeptidos utiles en diagnostico y tratamiento del cancer de prostata.
WO2003008647A2 (en) * 2000-11-28 2003-01-30 University Of Cincinnati Blood assessment of injury
MXPA03004637A (es) * 2000-11-28 2003-09-05 Wyeth Corp Analisis de expresion de acidos nucleicos y polipeptidos kiaa utiles en diagnostico y tratamiento de cancer de prostata.
AU2002219983A1 (en) 2000-12-06 2002-06-18 Northwestern University Silver stain removal from dna detection chips by cyanide etching or sonication
AU2002228841C1 (en) * 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7273923B2 (en) * 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US20090226915A1 (en) * 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US7405077B2 (en) * 2001-02-26 2008-07-29 Albany Medical College Sperm protein 17 for the diagnosis and treatment of cancer
US20060040286A1 (en) * 2001-03-28 2006-02-23 Nanosphere, Inc. Bio-barcode based detection of target analytes
WO2002081630A2 (en) * 2001-04-06 2002-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of semenogelin in the diagnosis, prognosis and treatment of cancer
FR2823092B1 (fr) * 2001-04-10 2004-03-05 Eurorad 2 6 Dispositif per-operatoire pour la localisation de tissus marques et procede utilisant un tel dispositif
EP1390078A4 (de) * 2001-04-26 2005-10-26 Analogic Corp Ct-scanner für die darstellung eines vorab festgelegten teils eines patienten
US7147687B2 (en) * 2001-05-25 2006-12-12 Nanosphere, Inc. Non-alloying core shell nanoparticles
AU2002239726A1 (en) 2001-05-25 2002-12-09 Northwestern University Non-alloying core shell nanoparticles
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
CA2457579A1 (en) 2001-08-14 2003-02-27 Mount Sinai School Of Medicine Use of intrinsic reporters of cell signaling for high content drug profiling and toxicity screening
DE60228128D1 (de) * 2001-11-09 2008-09-18 Nanosphere Inc Biokonjugat-nanopartikelsonden
CA2468408A1 (en) * 2001-11-28 2003-06-05 Genset S.A. Human cdnas and proteins and uses thereof
US20040058857A1 (en) * 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
WO2003048769A1 (en) * 2001-11-30 2003-06-12 Nanosphere, Inc. Real-time monitoring of pcr amplification using nanoparticle probes
US20050069889A1 (en) * 2001-12-21 2005-03-31 Naoki Nihei Novel metastasis suppressor gene on human chromosome 8
US7262054B2 (en) * 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US8008012B2 (en) 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
US7280680B2 (en) * 2002-03-04 2007-10-09 Riken Method and apparatus for observing three-dimensional localizations of in vivo expressed genes as well as method and apparatus for observing minute three-dimensional localizations of in vivo expressed genes
US20070233391A1 (en) * 2002-03-07 2007-10-04 Cambridge University Technical Service Limited (CUTS) Scd fingerprints
US20030211488A1 (en) * 2002-05-07 2003-11-13 Northwestern University Nanoparticle probs with Raman spectrocopic fingerprints for analyte detection
CA2490413C (en) * 2002-07-02 2011-08-30 Nanosphere, Inc. Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
US7361635B2 (en) * 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
AR044732A1 (es) * 2002-11-08 2005-10-05 H P B S A Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica
EP1597399A2 (de) * 2003-02-27 2005-11-23 Nanosphere, Inc. Markierungsfreie erstellung von genexpressionsprofilen mittels universeller nanopartikelsonden im mikroarray-testformat
US20100022414A1 (en) 2008-07-18 2010-01-28 Raindance Technologies, Inc. Droplet Libraries
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20050250094A1 (en) * 2003-05-30 2005-11-10 Nanosphere, Inc. Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes
US20050221339A1 (en) * 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US20060057613A1 (en) * 2004-07-26 2006-03-16 Nanosphere, Inc. Method for distinguishing methicillin resistant S. aureus from methicillin sensitive S. aureus in a mixed culture
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
US20070154903A1 (en) * 2005-06-23 2007-07-05 Nanosphere, Inc. Selective isolation and concentration of nucleic acids from complex samples
US20070029205A1 (en) * 2005-08-08 2007-02-08 Shoou-Aaey Chen Method of surface treatment for metal and nonmetal surfaces
ATE489482T1 (de) * 2005-08-19 2010-12-15 Nanosphere Inc Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon
AU2006335290A1 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
ES2300176B1 (es) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
EP4190448A3 (de) 2006-05-11 2023-09-20 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtungen
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US9162039B2 (en) * 2006-08-18 2015-10-20 David M. Hoganson Flow directed guidewire
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP2657699B1 (de) * 2007-10-02 2017-03-22 Theranos, Inc. Modulare POC-Vorrichtungen und ihre Verwendung
US20110136166A1 (en) * 2008-03-14 2011-06-09 Eastern Virginia Medical School Imaging Mass Spectrometry for Improved Prostrate Cancer Diagnostics
ES2668555T3 (es) 2008-05-27 2018-05-18 Dako Denmark A/S Composiciones y métodos para la detección de aberraciones cromosómicas con tampones de hibridación novedosos
ITRM20080310A1 (it) * 2008-06-12 2009-12-13 Ist Fisioterap Ospitalroma Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human pancreatic cancer cell lines.
EP2398504B1 (de) * 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Verfahren und Kits zur Diagnose von Krebs und Vorhersage des therapeutischen Nutzens
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US9046529B2 (en) 2009-04-10 2015-06-02 The Regents Of The University Of California Prostatitis-associated antigens and methods of use thereof
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
EP2534267B1 (de) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digitale analyse von analyten
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP2622103B2 (de) 2010-09-30 2022-11-16 Bio-Rad Laboratories, Inc. Sandwichassays in tröpfchen
EP2658996B1 (de) * 2010-12-30 2016-10-19 Hummingbird Diagnostics GmbH Komplexer satz aus mi-rnas als nichtinvasive biomarker für prostataerkrankungen
EP2673614B1 (de) 2011-02-11 2018-08-01 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
EP3736281A1 (de) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP2761028A1 (de) 2011-09-30 2014-08-06 Dako Denmark A/S Hybridisierungszusammensetzungen und -verfahren mit formamid
EP2768974B1 (de) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridisierungszusammensetzungen und -verfahren
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP2844768B1 (de) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digitale analyse von analyten
CN103674871B (zh) * 2012-09-19 2016-02-03 江南大学 一种综合判定啤酒酵母自溶情况的方法
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
RU2630648C2 (ru) * 2016-02-05 2017-09-11 Общество С Ограниченной Ответственностью "Биомаркер-Ру" Способ диагностики заболевания, сопровождающегося повышенной гибелью клеток, и набор для его осуществления
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
EP3699594A1 (de) 2019-02-22 2020-08-26 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Verwendung von bmmf1-rep-protein als ein biomarker für prostatakrebs
WO2022193993A1 (zh) * 2021-03-16 2022-09-22 上海柏全生物科技有限公司 精液凝固蛋白的中和抗体及其表位和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2250993B (en) * 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
EP0726956A1 (de) * 1991-12-31 1996-08-21 Zymogenetics, Inc. Neuartige humane transglutaminasen
JPH08502889A (ja) * 1992-10-29 1996-04-02 トーマス・ジェファーソン・ユニバーシティ 前立腺癌の微小転移を検出する方法
US5459037A (en) * 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US5677125A (en) * 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
AU2292495A (en) 1994-04-15 1995-11-10 Trustees Of Columbia University In The City Of New York, The Method for molecular staging of prostate cancer
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
WO1996021042A2 (en) 1995-01-04 1996-07-11 Trustees Of Boston University Primers for the pcr amplification of metastatic sequences

Also Published As

Publication number Publication date
CA2318354C (en) 2010-07-06
US5972615A (en) 1999-10-26
CA2707069A1 (en) 1999-07-29
CA2707152A1 (en) 1999-07-29
DE69933989T2 (de) 2007-07-05
CA2318354A1 (en) 1999-07-29
US6171796B1 (en) 2001-01-09
AU2327099A (en) 1999-08-09
US20010007748A1 (en) 2001-07-12
ATE345399T1 (de) 2006-12-15
AU746142B2 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
DE69933989D1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
Wechter et al. Vulvar melanoma: a report of 20 cases and review of the literature
WO1997036535A3 (en) Biomarkers for detection, diagnosis and prognosis of prostate cancer
Byrd et al. Advanced presentation of melanoma in African Americans
Fasching et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer
Kivisaari et al. Squamous cell carcinoma of the skin: emerging need for novel biomarkers
WO2005100998A3 (de) Membrane markers for use in cancer diagnosis and therapie
WO2006091776A3 (en) Biomarkers for predicting prostate cancer progression
Ferrucci et al. Host phenotype characteristics and MC1R in relation to early-onset basal cell carcinoma
EP2258872A3 (de) Genexpressionsprofilierung in einer Biopsie unterzogenem Tumorgewebe
ATE291614T1 (de) Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen
DK1530724T3 (da) Diagnose og forebyggelse af cancercelleinvasion
WO2002032292A3 (en) Methods for development and use of diagnostic and therapeutic agents
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
CN108624688A (zh) hsa_circ_0012755作为前列腺癌分子靶标在制备药物和试剂盒中的应用
Mousavi Ardehaie et al. Aberrant methylated EDNRB can act as a potential diagnostic biomarker in sporadic colorectal cancer while KISS1 is controversial
DE60234619D1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
ATE361993T1 (de) Diagnose und behandlung von prostatakrebs
ATE553112T1 (de) Ttk in der diagnose und als therapeutisches target bei krebs
Ramírez-de los Santos et al. Relation between personality dimensions and symptomatology of depression in skin cancer patients
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
Sultanbaev et al. 25P Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition